ArticleACG case reports journal2025
Nivolumab-Induced Refractory Hemorrhagic Gastritis and Duodenitis Requiring Multimodal Biologic Therapy.
Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rising immune checkpoint inhibitor use in modern cancer therapy has increased the incidence of immune-related adverse events. Although isolated upper gastrointestinal immune-related adverse events including gastritis and duodenitis are uncommon, they may be severe and potentially life-threatening. The heterogeneous presentation of immune-related gastritis and duodenitis causes diagnostic and therapeutic challenges. We present a rare case of severe hemorrhagic gastritis and duodenitis occurring 2 months after completion of nivolumab therapy for stage III melanoma. The disease proved refractory to intravenous pantoprazole, steroids, and infliximab alone, ultimately requiring the addition of vedolizumab in the short term. Complete clinical and biochemical remission was achieved after 12 months of infliximab, which was ceased a month later. Following cessation of immunomodulatory therapy, there was no recurrence of disease at 12-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.